Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
11.5.2022 16:00:00 EEST | Business Wire | Press release
Alira Health (www.alirahealth.com), a global healthcare advisory and technology company, today announced the acquisition of RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction were not disclosed.
RedCrow was launched in 2016 by Brian Smith, a former Morgan Stanley financial advisor, and Jerry Harrison, an entrepreneur and member of the Rock and Roll Hall of Fame with Talking Heads. RedCrow mines the “wisdom of the crowd” to help find companies that resonate with an audience that may not only use a product but also invest in and realize a return from the company that invented it. This acquisition extends Alira Health’s ability to partner with patients across the lifecycle of drug and device development into the financing phase for early-stage pharma, MedTech, and healthcare services solutions.
“From personal experience, the founders at RedCrow recognize that not every drug or device receives the right investment,” said Gabriele Brambilla, CEO, and founder of Alira Health. “By reinventing and democratizing the way early-stage companies get funded, RedCrow helps more healthcare solutions come to market that can save patients’ lives. Alira Health already partners with patients across the development lifecycle. With RedCrow, we can now involve patients, their care circles, and other investors in the financing phase for new products that may also improve their care outcomes.”
RedCrow’s Brian Smith added, “We founded RedCrow with the belief that healthcare investing should be more immediate, transparent, and accessible, and that patients and their family members should be able to help fund future developments that may impact their own care. We embrace Alira Health’s mission to humanize healthcare and view our platform as a natural extension of Alira Health’s business model. At the same time, early-stage companies on the RedCrow platform can benefit from the breadth of Alira Health’s extensive services offering.”
Since its founding, RedCrow has marketed over 250 fundraises totaling $250 million. Recent success stories include HeartBeam (NASDAQ: BEAT), Sen Jam Pharmaceutical, Activ Surgical and Centerline Biomedical.
About RedCrow
Headquartered in Mill Valley, Calif., RedCrow, which was created because of the 2012 Jobs Act, is a direct investment and marketing platform for healthcare innovation, providing curated deal flow for all investors. RedCrow leverages both the industry experts to provide comprehensive analysis on healthcare startups, enabling a wide array of investors to help healthcare innovation succeed. When a startup joins RedCrow, it's equipped with the tools it needs, like virtual deal rooms, to market its company and investment opportunity. RedCrow leverages the knowledge of its advisory board, which includes financial, scientific, and medical professionals, along with its online community of investors, healthcare professionals, and patients to identify and support innovative companies.
Learn more at https://www.redcrow.com/home/what-we-do.html. Follow RedCrow on Twitter (@RedCrowCrowd) at https://twitter.com/RedCrowCrowd and LinkedIn at https://www.linkedin.com/company/redcrow-crowd/.
About Alira Health
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.
Learn more at https://alirahealth.com/. Follow Alira Health on Twitter (@AliraHealth) at https://twitter.com/alirahealth and LinkedIn at https://www.linkedin.com/company/alira-health/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005026/en/
Contact information
Corporate
Susan Irving
Vice President of Global Marketing
susan.irving@alirahealth.com
Media
David Schull
President, Russo Partners LLC
david.schull@russopartnersllc.com
Olipriya Das
Senior Account Executive, Russo Partners LLC
olipriya.das@russopartnersllc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Solid Performance in 20253.3.2026 15:41:00 EET | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Company”) (stock code: HK:0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025. TTI delivered record sales of US$15.3 billion in 2025, growing 4.4% on a reported basis and 4.1% in local currency. Our two leading brands, MILWAUKEE and RYOBI, both delivered solid performances in 2025 with MILWAUKEE growing 7.9% and RYOBI growing 5.4% in local currency. TTI delivered record sales and earnings despite significant tariff headwinds, growing sales 4.4% to US$15.3 billion and net profit 6.8% to US$1.2 billion. Our Global MILWAUKEE business grew 8.1% on a reported basis with underlying sales rising 10.3% in local currency (excluding the discretionary suspension of certain second half promotions due to tariffs). RYOBI, the #1 global consumer cordless tool and outd
Quectel and MediaTek Unveil Next Generation 5G-A and Wi-Fi 8 Intelligent CPE Reference Design at MWC 20263.3.2026 15:38:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of a new intelligent CPE reference design based on the MediaTek T930 platform, integrating 5G-Advanced and Wi-Fi 8 technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303124613/en/ Quectel and MediaTek unveil next generation 5G-A and Wi-Fi 8 intelligent CPE reference design at MWC 2026 The solution combines the high-performance 5G-A connectivity, intelligent reliability and advanced capabilities of the MediaTek T930 platform with Quectel’s deep expertise in the global Fixed Wireless Access (FWA) market. Moving beyond a simple focus on high speed, it delivers a fully integrated, all-in-one solution featuring exceptional performance, ultra-high stability, and intelligent network management. Designed for both residential and enterprise users, the solution enables transformative improvements in broadband access, mobile
Riskified Announces Expansion of AI Agent Intelligence to Secure Native Merchant AI Shopping Assistants3.3.2026 15:00:00 EET | Press release
Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced an expansion of its AI Agent Intelligence platform, positioning the company as the definitive shield for the next era of ecommerce. As merchants explore deploying their own native, conversational AI shopping assistants to elevate their customer experience, Riskified is ensuring that these new touchpoints are protected from sophisticated fraud and abuse. Retailers are heavily investing in bringing AI agents directly to their digital storefronts. Research from McKinsey & Company underscores this trend, noting that 82% of retail organizations have already launched generative AI pilots focused on reinventing customer service. As merchants build out their AI shopping assistants to offer deep personalization and loyalty programs based on customer preferences, Riskified provides a critical risk intelligence layer that makes these interactions both smart and secure. Because Riskified analyzes the complet
PAX Unveils Long-Anticipated PAX FOUR, Its Most Powerful Dry Herb Vaporizer Yet3.3.2026 15:00:00 EET | Press release
Nearly two decades after defining the category, PAX today announced the launch of PAX FOUR, the most powerful dry herb vaporizer in the company’s history. Built for consumers who want dense vapor and immediate impact without combustion, PAX FOUR delivers smoking-level intensity you can see and feel in a sleek, precision-engineered device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740648/en/ PAX FOUR, the most powerful dry herb vaporizer in the company’s history. The cannabis vaporization category continues to grow as consumers shift away from smoking and combustion, yet many remain loyal to traditional smoking methods, often citing weak vapor, lack of intensity, and inconsistent performance from existing devices. PAX FOUR was engineered to change that — producing larger clouds and consistent performance while preserving PAX’s signature portability and design. “PAX FOUR is all about power,” said Chris Ahern, CEO of
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria3.3.2026 15:00:00 EET | Press release
The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303556687/en/ The manufacturing agreement brings together PRF’s decades-long, research-driven Progeria program with Forge’s integrated gene therapy capabilities including process development, cGMP manufacturing, FUEL™ platform technologies, and regulatory consultation. Forge will provide manufacturing services for Investiga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom